Jazz Pharmaceuticals (JAZZ) Total Non-Current Liabilities (2011 - 2026)

Jazz Pharmaceuticals' Total Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $11.7 billion for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 2.22% year-over-year to $11.7 billion in Q1 2026; TTM through Mar 2026 was $11.7 billion, a 2.22% increase from a year earlier, with the FY2025 full-year figure at $11.5 billion, down 3.28% from the prior year.
• Total Non-Current Liabilities climbed to $11.7 billion in Q1 2026 per JAZZ's latest filing, from $11.5 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $12.1 billion in Q3 2024 and bottomed at $10.3 billion in Q3 2022.
• The 5-year median for Total Non-Current Liabilities is $11.2 billion (2025), against an average of $11.3 billion.
• Biggest YoY gain for Total Non-Current Liabilities was 75.09% in 2022; the steepest drop was 16.85% in 2022.
• Year by year, Total Non-Current Liabilities stood at $10.7 billion in 2022, then increased by 5.42% to $11.3 billion in 2023, then climbed by 5.81% to $11.9 billion in 2024, then decreased by 3.28% to $11.5 billion in 2025, then increased by 1.41% to $11.7 billion in 2026.
• Per Business Quant, the three latest JAZZ Total Non-Current Liabilities figures stand at $11.7 billion (Q1 2026), $11.5 billion (Q4 2025), and $11.2 billion (Q3 2025).